Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat in COPD
NCT00168844Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2003
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change From Baseline in Trough FEV1 at Week 48, Saint George's Respiratory Questionnaire Total Score at Week 48 and 2 more. Started Jan 2003; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00168844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168844.